Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?

Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?

Long Investing Ideas from Seeking Alpha

Wed, 6 Feb 2013

By Prohost Biotech : We lived a long time with Elan ( ELN ) . We always appreciated its science and scientists, and, at times, we hated its former management, or whoever caused it to turn from ascending towards becoming a citadel of sciences, especially neurosciences, into an almost bankrupt firm ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Related Videos

  1. No Sign of Slowdown in Biotech M&A

    Tue, 10 May 2011

    High levels of merger and acquisition activity will be the big theme of year for biotech , says Morningstar's Lauren Migliore.

  2. Our Top Five Biotech Acquisition Candidates

    Thu, 17 Mar 2011

    M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.